Antengene's partner karyopharm therapeutics announces updated data of eltanexor in patients with hypomethylating agent refractory mds

--of the 15 patients evaluable for efficacy, 7 (47%) had mcr and 5 (33%) had sd for a total disease control rate of 80%-- --patients with mcr had longer mos than patients without mcr or with pd-- shanghai and hong kong, june 8, 2021 /prnewswire/ -- antengene's partner, karyopharm therapeutics inc. (nasdaq: kpti), announced updated data of eltanexor for the treatment of patients with hypomethylating agent (hma) refractory myelodysplastic syndrome (mds) at the 2021 american society of clinical oncology (asco) annual meeting. this phase i/ii study evaluated single-agent eltanexor in patients with higher-risk mds, ie, high-risk or intermediate-2 mds by the international prognostic scoring system (ipss) and 5%-19% myeloblasts.
KPTI Ratings Summary
KPTI Quant Ranking